Verona Pharma plc reported earnings results for the third quarter ended September 30, 2023. For the third quarter, the company reported net loss was USD 14.69 million compared to USD 15.65 million a year ago. Basic loss per share from continuing operations was USD 0.16 compared to USD 0.24 a year ago.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
12.09 USD | -2.74% | -4.33% | -39.36% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-39.36% | 1.01B | |
+8.90% | 115B | |
+9.65% | 105B | |
-12.96% | 22.71B | |
+2.21% | 21.83B | |
-10.88% | 18.18B | |
-41.92% | 16.52B | |
-16.28% | 16.01B | |
+1.54% | 14.14B | |
+17.81% | 10.71B |
- Stock Market
- Equities
- VRNA Stock
- News Verona Pharma plc
- Verona Pharma plc Reports Earnings Results for the Third Quarter Ended September 30, 2023